
Advances in science are changing how we fight respiratory infections. Introducing Pfizer’s research study for an investigational combination vaccine that may protect against COVID-19 and RSV in one convenient shot.
Advances in science are changing how we fight respiratory infections. Introducing Pfizer’s research study for an investigational combination vaccine that may protect against COVID-19 and RSV in one convenient shot.
You have the power to advance research that may change the future of seasonal influenza (flu) with 1 injection. Learn more about participating in the Ignite P303 Trial for an investigational vaccine aimed at preventing seasonal flu infection.
Seasonal flu vaccines during the 2021-2022 flu season were2:
A messenger RNA (mRNA) vaccine may offer broader protection by responding to changes in seasonal flu strains more quickly and creating stronger immune responses3.
The Ignite P303 Trial will look at the safety and immune response of an mRNA-based investigational vaccine aimed at preventing seasonal flu in adults aged 18 and older.
Who Can Join?
This clinical trial is looking for adult participants. To join, you must be:
⚪ 18 years of age or older
⚪ In good health
⚪ Not pregnant or planning on becoming pregnant for at least 3 months following your vaccine visit
Prior to enrolling in this trial, you should:
⚪ Not have received a seasonal flu vaccine in the past 5 months
⚪ Not have had a confirmed flu infection within 5 months
References:
1. Influenza (seasonal): ask the expert: influenza Q&A. World Health Organization. Published November 6, 2018. https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal)
2. Price AM, Flannery B, Talbot HK, et al. Influenza vaccine effectiveness against influenza A(H3N2)-related illness in the United States during the 2021-2022influenza season. Clin Infect Dis. 2022;ciac941. doi:10.1093/cid/ciac941
3. Rockman S, Laurie KL, Parkes S, Wheatley A, Barr IG. New technologies for influenza vaccines. Microorganisms. 2020;8(11):1745.